[1]林杜生,周昭涛,黄晓琼,等.反复玻璃体内注射阿柏西普对黄斑水肿患者角膜的影响[J].眼科新进展,2021,41(4):368-370.[doi:10.13389/j.cnki.rao.2021.0077]
　LIN Dusheng,ZHOU Zhaotao,HUANG Xiaoqiong,et al.Effect of repeated intravitreal aflibercept injections on the cornea in patients with macular edema[J].Recent Advances in Ophthalmology,2021,41(4):368-370.[doi:10.13389/j.cnki.rao.2021.0077]
点击复制

反复玻璃体内注射阿柏西普对黄斑水肿患者角膜的影响/HTML
分享到：

《眼科新进展》[ISSN:1003-5141/CN:41-1105/R]

卷:
41卷
期数:
2021年4期
页码:
368-370
栏目:
应用研究
出版日期:
2021-04-05

文章信息/Info

Title:
Effect of repeated intravitreal aflibercept injections on the cornea in patients with macular edema
作者:
林杜生; 周昭涛; 黄晓琼; 肖亮伊; 张少斌
515041　广东省汕头市，汕头博德眼科医院
Author(s):
LIN Dusheng; ZHOU Zhaotao; HUANG Xiaoqiong; XIAO Liangyi; ZHANG Shaobin
Shantou Bode Eye Hospital,Shantou 515041,Guangdong Province,China
关键词:
角膜; 阿柏西普; 黄斑水肿; 玻璃体内注射; 安全性
Keywords:
cornea;  aflibercept;  macular edema;  intravitreal injection;  safety
分类号:
R774.5
DOI:
10.13389/j.cnki.rao.2021.0077
文献标志码:
A
摘要:
目的　观察反复玻璃体内注射阿柏西普对黄斑水肿患者的角膜内皮细胞和中央角膜厚度的影响。方法　选取2018年3月至2020年10月在我院行玻璃体内注射阿柏西普治疗黄斑水肿的患者46例46眼。每位患者均接受玻璃体内注射阿柏西普2 mg/0.05 mL，每月1次，连续注射3次。对比分析注药前1 d和注药后1个月、3个月、5个月患眼眼压、中央角膜厚度、角膜内皮细胞密度、六边形细胞比例、角膜内皮细胞面积变异系数和角膜内皮细胞数的变化。结果　注药前1 d和注药后1个月、3个月、5个月患眼中央角膜厚度分别为（538.85±31.87）μm、（536.02±30.87）μm、（535.43±31.48）μm、（536.46±32.50）μm，差异无统计学意义（P>0.05）。注药前1 d和注药后1个月、3个月、5个月，患眼眼压差异无统计学意义（P>0.05）。注药前1 d和注药后1个月、3个月、5个月患眼角膜内皮细胞密度分别为（2678.72±421.72）个·mm-2、（2658.30±461.71）个·mm-2、（2661.96±407.26）个·mm-2、（2656.41±427.74）个·mm-2，差异无统计学意义（P=0.611）。注药前和注药后1个月、3个月、5个月相比，患眼六边形细胞比例、角膜内皮细胞面积变异系数、角膜内皮细胞数差异均无统计学意义（均为P>0.05）。结论　反复玻璃体内注射阿柏西普，短期内对角膜内皮细胞的形态和中央角膜厚度没有明显影响。
Abstract:
Objective　To observe the effects of repeated intravitreal aflibercept injection (IAI) on the corneal endothelium and center corneal thickness in patients with macular edema.Methods　IAI was performed on 46 eyes of 46 patients with macular edema from Mar. 2018 to Oct. 2020. Each patient received IAI 2mg/0.05mL monthly for three consecutive months. Intraocular pressure, central cornea thickness, corneal endothelial cell density, percentage of hexagonal cells, coefficient of variation of cell area, and number of endothelial cells in the treated eyes 1 day before injection and 1 month, 3 months and 5 months after injection were analyzed.Results　The center corneal thickness of the treated eyes were (538.85±31.87)μｍ 1 day before surgery, and (536.02±30.87) μｍ, (535.43±31.48) μｍ,(536.46±32.50) μｍ at month 1, 3 and 5 after injection, respectively, with no statistical significance (P>0.05). There were no statistically significant differences in intraocular pressure 1 day before injection and 1 month,3 months, and 5 months after injection (all P>0.05).The endothelial cell density were (2678.72±421.72) cells·mm-2 1 day before injection, and (2658.30±461.71) cells·mm-2, (2661.96±407.26) cells·mm-2,(2656.41±427.74) cells·mm-2, at month 1, 3 and 5 after injection, respectively (P=0.611). Percentage of hexagonal cells, coefficient of variation of cell area, and number of endothelial cells in the treated eyes at baseline and month 1, 3 and 5 after injection were compared, and there were no significant differences (all P>0.05). Conclusion　Repeated IAI monthly for three months seems no effect on corneal endothelial and central cornea thickness at 5 months after IAI.

参考文献/References:

［1］　WONG T Y,SUN J,KAWASAKI R,RUAMVIBOONSUK P,GUPTA N,LANSINGH V C,et al.Guidelines on diabetic eye care: The international council of ophthalmology recommendations for screening,follow-up,referral,and treatment based on resource settings［J］.Ophthalmology,2018,125(10):1608-1622.
［2］　SIVAPRASAD S,AMOAKU W M,HYKIN P,RVO Guideline Group.The Royal College of Ophthalmologists Guidelines on retinal vein occlusions: executive summary［J］.Eye,2015,29(12):1633-1638.
［3］　SCHMIDT-ERFURTH U,CHONG V,LOEWENSTEIN A,LARSEN M,SOUIED E,SCHLINGEMANN R,et al.Guidelines for the management of neovascular age-related macular degeneration by the European Society of Retina Specialists (EURETINA) ［J］.Br J Ophthalmol,2014,98(9):1144-1167.
［4］　卢谦益.阿柏西普经玻璃体内注射治疗糖尿病黄斑水肿的临床疗效［J］.眼科新进展， 2019， 39(4) : 340-342．
LU Q Y.Intravitreal aflibercept injection for the treatment of diabetic macular edema［J］.Rec Adv Ophthalmol,2019，39(4):340-342.
［5］　DE OLIVEIRA DIAS J R，DE ANDRADE G C，NOVAIS E A，FARAH M E,RODRIGUES E B.Fusion proteins for treatment of retinal diseases: aflibercept,ziv-aflibercept，and conbercept［J］.Int J Retina Vitreous，2016，2(1):3．
［6］　SUN Z,ZHOU H,LIN B,JIAO X,LUO Y,ZHANG F,et al.Efficacy and safety of intravireal conbercept injections in macular edema secondary to retinal vein occlusion［J］.Retina,2017,37(9):1723-1730.
［7］　LU Q,LU L,CHEN W,CHEN H,XU X,ZHENG Z.RhoA/mDia-1/profilin-1 signaling targets microvascular endothelial dysfunction in diabetic retinopathy［J］.Graefes Arch Clin Exp Ophthalmol,2015,253(5):669-680.
［8］　LU Q,LU P,CHEN W,LU L,ZHENG Z.ANGPTL-4 induces diabetic retinal inflammation by activating Profilin-1［J］.Exp Eye Res,2018,166:140-150.
［9］　PAPADOPOULOS N,MARTIN J,RUAN Q,RAFIQUE A,ROSCONI M P,SHI E,et al.Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap,ranibizumab and bevacizumab［J］.Angiogenesis,2012,15(2):171-185.
［10］　NIEDERER R L,PERUMAL D,SHERWIN T,MCGHEE C N.Age-related differences in the normal human cornea: a laser scanning in vivo confocal microscopy study［J］.Br J Ophthalmol,2007,91(9):1165-1169.
［11］　JOYCE N C.Proliferative capacity of the corneal endothelium［J］.Prog Retin Eye Res,2003,22:359-389.
［12］　FORRESTER J V,DICK A D,MC P,LEE W.The eye: Basic science in practice［M］.London: WB Saunders,1996.
［13］　PHILIPP W,SPEICHER L,HUMPEL C.Expression of vascular endothelial growth factor and its receptors in inflamed and vascularized human corneas［J］.Invest Ophthalmol Vis Sci， 2000,41（9）:2514-2522.
［14］　CABRAL T,LIMA L H,POLIDO J,DUONG J,OKUDA ,OSHIMA A,et al.Aqueous vascular endothelial growth factor and clinical outcomes correlation after single intravitreal injection of bevacizumab in patients with neovascular age-related macular degeneration［J］.Int J Retina Vitreous，2017,3:6.
［15］　CELIK N,SCHEUERLE A,AUFFARTH G U,KOPITZ J,DITHMAR S.Intraocular pharmacokinetics of aflibercept and vascular endothelial growth factor-a［J］.Invest Ophthalmol Vis Sci,2015,56(10):5574-5578.
［16］　WANG X,SAWADA T,KAKINOKI M,MIYAKE T,KAWAMURA H,SAISHIN Y,et al.Aqueous vascular endothelial growth factor and ranibizumab concentrations after monthly and bimonthly intravitreal injections of ranibizumab for age-related macular degeneration［J］.Graefes Arch Clin Exp Ophthalmol,2014,252(6):1033-1039.
［17］　ARI S,NERGIZ Y,AKSIT I,SAHIN A,CINGU K,CACA I.Evaluation of intracameral injection of ranibizumab and bevacizumab on the corneal endothelium by scanning electron microscopy［J］.J Ocul Pharmacol Ther,2015,31(2):100-105.
［18］　El CHEHAB H,AGARD E,RUSSO A,BOUJNAH Y,DOT C.Intraocular pressure spikes after aflibercept intravitreal injections［J］.Ophthalmologica,2016,236(1):43-47.
［19］　KAISER P K,SINGER M,TOLENTINO M,VITTI R,ERICKSON K,SAROJ N,et al.Long-term safety and visual outcome of intravitreal aflibercept in neovascular age-related macular degeneration: VIEW 1 extension study［J］.Ophthamol Retina,2017,1(4):304-313.
［20］　SCHMIDT-ERFURTH U,KAISER P K,KOROBELNIK J F,BROWN D M,CHONG V,NGUYEN Q D ,et al.Intravitreal aflibercept injection for neovascular age-related macular degeneration: ninety-six-week results of the VIEW studies［J］.Ophthalmology,2014,121(1):193-201.
［21］　FAUSER S,SCHWABECKER V,MUETHER P S.Suppression of intraocular vascular endothelial growth factor during aflibercept treatment of age-related macular degeneration［J］.Am J Ophthalmol,2014,158(3):532-536.
［22］　HEIER J S,BROWN D M,CHONG V,KOROBELNIK J F,KAISER P K,NGUYEN Q D,et al．Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration［J］.Ophthalmology,2012,119(12):2537-2548.

相似文献/References:

[1]王存 薛芸霞 杨亚兵 傅婷 李志杰 夏潮涌.小鼠出生前后角膜神经分布的变化[J].眼科新进展,2012,32(6):000.
[2]李雪 赵延军 张丽 胡琦 王珂萌.近视眼患者LASIK和LASEK术后角膜后表面变化的比较研究[J].眼科新进展,2012,32(6):000.
[3]赵伟 周瑾 郭梦翔 项道满.地塞米松对碱烧伤后大鼠角膜核转录因子-κB活化的影响[J].眼科新进展,2013,33(7):000.
[4]张研 陆晓和.角膜血管新生机制与调控新进展[J].眼科新进展,2008,28(9):000.
[5]王茜 吴良成 李铭.准分子激光角膜屈光手术后非球面系数的影响因素[J].眼科新进展,2012,32(4):000.
[6]付馨余 邹文进 黄明汉 赵静博.多西环素对碱烧伤大鼠角膜组织中NF-κB和bcl-2表达的影响[J].眼科新进展,2013,33(4):000.
[7]闵捷 胡丹 孙丽娟 雷润佳 王鹤霏 蔡莉.紫外光核黄素胶原交联对兔角膜碱烧伤作用的实验研究[J].眼科新进展,2013,33(5):000.
[8]白华 黄一飞.Boston型人工角膜的临床并发症及其处理[J].眼科新进展,2013,33(9):000.
[9]唐敏 席兴华 唐罗生 岳丽菁.人羊膜匀浆提取液对兔角膜成纤维细胞增殖和TGF-β1mRNA表达的影响[J].眼科新进展,2013,33(11):000.
[10]李海中 彭清华 王芬 姚小磊 李文娟.密蒙花总黄酮对去势雄鼠角膜组织Fas、FasL表达的影[J].眼科新进展,2013,33(12):000.

备注/Memo

备注/Memo:
N/A
更新日期/Last Update: 2021-04-05